Profile image
Story Views

Last Hour:
Last 24 Hours:

Netupitant-Palonosetron FDC Market Expected to Register High Revenue Growth Through 2014-2022

Tuesday, February 28, 2017 2:37
% of readers think this story is Fact. Add your two cents.

(Before It's News)

The press releases (PRs) on “Netupitant-Palonosetron FDC Market” added by Big Market Research will enable major enterprises unlocks the real-time data pertaining to the overall industry performance across different regions.

The fixed dose combination (FDC) of netupitant and palonosetron is a product proposed for the treatment of the most common side effects of chemotherapy-nausea and vomiting. The product is currently in its third stage of trial. Netupitant is a novel and a NK1 receptor antagonist, and palonosetron is a second-generation 5-HT3 receptor antagonist. While netupitant was not available in the drug market earlier, palonosetron drugs were already present under trade names Paloxi, Onicit, and Aloxi. The combination drug is expected to overcome major problems associated with the current mode of treatment of the CINV condition, which involves the use of 5-HT3 receptor antagonists.

Enquire about the discount on Report here:

The netupitant-palonosetron FDC market is driven by rise in number of patients who undergo chemotherapy. The market is segmented on the basis of patient pool and geography. Currently, pharmaceutical companies are increasingly investing in the further discovery of FDC drugs to achieve increased industry leading breadth and depth of clinical research.

However, factors such as adverse effect of netupitant-palonosetron FDC and high cost of drugs for patients act as restraints for the growth and development of the market. The new approaches and advancement in netupitant-palonosetron FDC market is the development in efficacy and potential of new FDC drugs. The foundation of combination therapy is projected to build up in broad spectrum. Netupitant–palonosetron, by trade name of Akynzeo, is approved and witnesses an increasing traction in the U.S. and European region.

Enquire about the Complete Report here:

The classes of drugs used in the treatment of CINV are 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, dopamine antagonists, benzodiazepines, and cannabinoids. However, Akynzeo is mostly used in the treatment, and is helpful in the prevention of nausea and vomiting due to long-lasting action, with no major adverse effects.

Geographically, the global netupitant-palonosetron FDC market is segmented into North America, Europe, Asia-Pacific, and LAMEA. In terms of growth rate, Asia-Pacific is expected to remain dominant over the forecast period, followed by Europe. North America, on the other hand, is expected to increase at a steady pace due to its steady growth in number of cancer patients opting for chemotherapy.

Major players profiled in the report includes Helsinn Holding S.A., Heron Therapeutics, Inc., Eisai Pharmaceutical Pvt. Ltd., and Tesaro, Inc.

To Order For a Sample Report Copy, Please Visit:


  • This report provides an extensive analysis of the current & emerging market trends and dynamics in the global netupitant–palonosetron FDC market.
  • This report entails the detailed quantitative analysis of the current trends and future estimations from 2014 to 2022, which assists to identify the prevailing market opportunities.
  • This study evaluates competitive landscape and value chain to understand the competitive environment across the geographies.
  • Comprehensive analysis of factors that drive and restrict the growth of the market is provided.

    About Us:

Our strength is in our research analysts who with their proactive approach are able to source best and correct information which can be detrimental in organizations success. We follow six sigma standards leaving no scope for error.

Big Market Research uniqueness lies in its highly ethical reports at economical rates because we value your relationship and growth more than money. Your growth is our aim.

Contact Big Market Research:

Direct Contact: + 1-503-894-6022
Toll Free: + 1-800-910-6452

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.